Meeting NewsVideo

VIDEO: Large, real-world analysis provides new insights on apixaban for nonvalvular AF

PARIS — In this video exclusive, P. Gabriel Steg, MD, FESC, provides investigator insight on NAXOS, the largest real-world analysis on the effectiveness and safety of apixaban compared with a vitamin K antagonist in Europe among patients with nonvalvular atrial fibrillation.

The NAXOS analysis included nearly the entire French population with nonvalvular AF, Steg, director of the coronary care unit in the cardiology department at Hôpital Bichat and professor of cardiology at the Université Paris – Diderot, told Cardiology Today.

According to data presented at the European Society of Cardiology Congress, apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) was associated with a lower rate of major bleeding, stroke and systemic thrombotic events.

Watch the video for more.

PARIS — In this video exclusive, P. Gabriel Steg, MD, FESC, provides investigator insight on NAXOS, the largest real-world analysis on the effectiveness and safety of apixaban compared with a vitamin K antagonist in Europe among patients with nonvalvular atrial fibrillation.

The NAXOS analysis included nearly the entire French population with nonvalvular AF, Steg, director of the coronary care unit in the cardiology department at Hôpital Bichat and professor of cardiology at the Université Paris – Diderot, told Cardiology Today.

According to data presented at the European Society of Cardiology Congress, apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) was associated with a lower rate of major bleeding, stroke and systemic thrombotic events.

Watch the video for more.

    See more from European Society of Cardiology Congress